Ebola virus disease treatment research

There is no cure or specific treatment for the Ebola virus disease that is currently approved for market, although various experimental treatments are being developed.[1] For past and current Ebola epidemics, treatment has been primarily supportive in nature.[2]

This article is about current experimental treatments to fight the Ebola virus. For vaccine information, see Ebola vaccine.

Researcher working with the Ebola virus while wearing a BSL-4 positive pressure suit

As of August 2019, two experimental treatments known as atoltivimab/maftivimab/odesivimab and ansuvimab were found to be 90% effective.[3][4][5][6]

In October 2020, the U.S. Food and Drug Administration (FDA) approved atoltivimab/maftivimab/odesivimab with an indication for the treatment of infection caused by Zaire ebolavirus.[7]

Overview
Articles related to the
Western African
Ebola virus epidemic
Overview
Nations with widespread cases
Other affected nations
Other outbreaks

In March 2014, the World Health Organization (WHO) reported a major Ebola outbreak in Guinea, a western African nation.[8] The disease then rapidly spread to the neighboring countries of Liberia and Sierra Leone. The 2014 West African Ebola outbreak is the largest Ebola outbreak ever documented, and the first recorded in the region.[8]

The director of the US National Institute of Allergy and Infectious Diseases (NIAID) has stated that the scientific community is still in the early stages of understanding how infection with the Ebola virus can be treated and prevented.[9] The unavailability of treatments in the most-affected regions has spurred controversy, with some calling for experimental drugs to be made more widely available in Africa on a humanitarian basis, and others warning that making unproven drugs widely available would be unethical, especially in light of past experimentation conducted in developing countries by Western drug companies.[10][11] As a result of the controversy, on 12 August an expert panel of the WHO endorsed the use of interventions with as-yet-unknown effects for both treatment and prevention of Ebola, and also said that deciding which treatments should be used and how to distribute them equitably were matters that needed further discussion.[12]

Conventional trials to study efficacy by exposure of humans to the pathogen are obviously not feasible in this case. For such situations, the Food and Drug Administration (FDA) has established the "animal efficacy rule" allowing limited licensure to be approved on the basis of animal model studies that replicate human disease, combined with evidence of safety. A number of experimental treatments are being considered for use in the context of this outbreak, and are currently or will soon undergo clinical trials.[13] A distributed computing project, Outsmart Ebola Together, has been launched by World Community Grid in collaboration with the Scripps Research Institute to help find chemical compounds to fight the disease. It uses the idle processing capacity of volunteers' computers and tablets.[14]

The centre for epidemic and microbiological research and treatment was constructed in the Guinean Kindia province. The centre was designed and created by RUSAL specialists with the assistance of Rospotrebnadzor scientists (RUSAL has invested $10 million).[15]

Experimental treatments being researched

Antibodies
  • ZMapp is a combination of three chimeric monoclonal antibodies effective in Ebola-infected monkeys.[16] Due to a limited supply of the antibody preparation, it was used to treat a small number of individuals infected with the Ebola virus early in the 2014–15 West Africa outbreak; although some individuals recovered, the outcome is not considered statistically significant.[17][18] The National Institutes of Health announced on 27 February 2015, the commencement of a randomized controlled trial of ZMapp to be conducted in Liberia and the United States.[19] From March 2015, through November 2015, 72 individuals infected with the Ebola virus were enrolled in the trial; investigators stopped enrolling new subjects in January 2016, having failed to reach its enrollment goal of 200 due to the waning of the Ebola outbreak. As a result, although a 40% lower risk of death was calculated for those who received ZMapp, the difference was not statistically significant and ultimately it could not be determined whether the use of ZMapp was superior to the optimized standard of care alone. However, ZMapp was found to be safe and well tolerated.[20][21][22] ZMapp was discontinued in the 2018–19 Kivu Ebola epidemic.[23]
  • The mAb114 monoclonal antibody was derived from an EVD survivor of the 1995 DRC outbreak in Kikwit. It binds to the glycoprotein cap of the virus. As of 2016, it had not been tested in humans, but been tested in three non-human primates; it worked less well at preventing disease when given alone than in combination with another mAb.[24][25][26] As of 2019, it was found to be safe and effective for humans.[5][27][3][4]

Antivirals and other drugs
  • Favipiravir (Avigan) is a broad-spectrum antiviral drug, used to treat influenza,[22] which in a mouse model appears to be useful in treating Ebola disease.[28][29] A phase two clinical trial started in Guinea during December 2014,[30][31] with early reports indicating that it has some benefit.[32]
  • Ribavirin, an antiviral drug, delayed death and increased survival rate in both mouse and monkey models; adverse effects, such as birth defects and red blood cell breakdown, limit its use.[22]
  • BCX4430 is a broad-spectrum nucleoside analog antiviral drug developed by BioCryst Pharmaceuticals.[33] A phase one trial started in December 2014.[34][35] The drug was effective in Ebola-infected monkeys.[36]
  • Brincidofovir, an antiviral drug, has been granted an emergency FDA approval as an investigational new drug for the treatment of Ebola after it was found to be effective against Ebola virus in in vitro tests.[37] A phase two trial started during January 2015 in Liberia, but was subsequently discontinued due to a lack of suitable subjects.[38][39][40]
  • TKM-Ebola is an RNA interference drug candidate; a Phase II trial started on 11 March 2015, and stopped enrolling new subjects on 19 June 2015, after it appeared not to work; statistical analysis was ongoing at the time.[41][42]
  • AVI-7537 is an antiviral drug developed by Sarepta Therapeutics, which was effective in Ebola-infected monkeys.[43][44] A phase one trial May 2010, to November 2011, showed that the drug was safe in healthy adults;[45][46] however, a later phase one trial was withdrawn due to funding constraints.[47]
  • JK-05 is an antiviral drug developed by Sihuan Pharmaceutical along with Academy of Military Medical Sciences. In tests on mice, JK-05 shows efficacy against a range of viruses, including Ebola. It is claimed to have a simple molecular structure, which should be readily amenable to synthesis scale-up for mass production. The drug has been given preliminary approval by the Chinese authorities to be available for Chinese health workers involved in combating the outbreak, and Sihuan are preparing to conduct clinical trials in West Africa.[48][49]

Blood products

The World Health Organization (WHO) has stated that transfusion of whole blood or purified serum from Ebola survivors has the greatest potential to be implemented immediately, and has issued an interim guideline for this therapy.[50] A study in Sierra Leone started in November 2014, and preliminary results show an 80 percent survival rate.[51] Trials in Liberia and Guinea started in January 2015, with funding from the Gates Foundation.[52] Blood transfusions were also used in a 1995 outbreak in the Democratic Republic of the Congo, and 7 out of 8 patients survived.[53]

Existing drugs without anti-Ebola activity

Ribavirin is also known to be ineffective against ebolaviruses despite its effectiveness against other viral hemorrhagic fevers such as Lassa fever.[54] Interferon therapies have been tried as a form of treatment for EVD, but were found to be ineffective.[55]

Potential diagnostic tests

One issue which hinders control of Ebola is that diagnostic tests that are currently available require specialised equipment and highly trained personnel. Since there are few suitable testing centres in West Africa, this leads to delay in diagnosis. In December, a conference in Geneva will aim to work out which diagnostic tools could identify Ebola reliably and more quickly. The meeting, convened by the WHO and the non-profit Foundation for Innovative New Diagnostics, seeks to identify tests that can be used by untrained staff, do not require electricity or can run on batteries or solar power and use reagents that can withstand temperatures of 40 °C (104 °F).[56]

As of February  2015, a number of diagnostic tests are under trial:

  • Diagnostics-in-a-Suitcase, based on recombinase polymerase amplification (RPA). The new equipment, about the size of a laptop and solar-powered, allows testing to be done in remote areas; testing commenced in Guinea during January 2015.[57]
  • In December 2014, the FDA approved LightMix Ebola Zaire rRT-PCR Test for emergency use on patients with symptoms of Ebola.[58]
  • Massachusetts Institute of Technology developed a 10-minute Ebola test using Matrix Multiplexed Diagnostic (MMDx) technology. It still has to complete testing to gain FDA approval.[59]
  • Corgenix Medical Corp announced on 26 February 2015, that health regulators had approved its rapid Ebola test for emergency use. The ReEBOV Antigen Rapid Test involves putting a drop of blood on a paper strip and waiting for at least 15 minutes for a reaction.[60]
  • On 29 March 2015, a new rapid Ebola virus diagnostic kit/test was developed by British military scientists and NHS in Sierra Leone.[61]

Hemopurifier

The Hemopurifier is a single-use disposable biological cartridge designed for use with dialysis machines and other blood circulatory pumps. It is a method for removal of viruses from blood by lectin affinity hemodialysis which embodies reducing viral loads in the blood of individuals infected with a virus.[62] During October 2014, the Hemopurifier was used as an adjunct in the treatment of a patient with Ebola, who then recovered.[63] The FDA subsequently approved the device for testing in up to 20 infected Ebola cases in the United States.[64]

See also

References
  1. Choi JH, Croyle MA (December 2013). "Emerging targets and novel approaches to Ebola virus prophylaxis and treatment". BioDrugs. 27 (6): 565–83. doi:10.1007/s40259-013-0046-1. PMC 3833964. PMID 23813435.
  2. Clark DV, Jahrling PB, Lawler JV (September 2012). "Clinical management of filovirus-infected patients". Viruses. 4 (9): 1668–86. doi:10.3390/v4091668. PMC 3499825. PMID 23170178.
  3. McNeil Jr DG (12 August 2019). "A Cure for Ebola? Two New Treatments Prove Highly Effective in Congo". The New York Times. Retrieved 12 August 2019. The two new therapies were among four that were tested in a trial that has enrolled almost 700 patients since November. The two worked so well that a committee meeting on Friday to look at preliminary results in the first 499 patients immediately recommended that the other two treatments, ZMapp, made by Mapp Biopharmaceutical, and remdesivir, made by Gilead Sciences, be stopped. All patients will now be offered either the Regeneron or the Biotherapeutics drug.
  4. Maxmen A (12 August 2019). "Two Ebola drugs show promise amid ongoing outbreak". Nature. doi:10.1038/d41586-019-02442-6. ISSN 0028-0836. PMID 32778704. S2CID 201975390.
  5. Hoenen T, Groseth A, Feldmann H (24 July 2019). "Therapeutic strategies to target the Ebola virus life cycle". Nature Reviews. Microbiology. 17 (10): 593–606. doi:10.1038/s41579-019-0233-2. ISSN 1740-1526. PMID 31341272.
  6. "Investigational Monoclonal Antibody to Treat Ebola Is Safe in Adults" (Press release). National Institute of Allergy and Infectious Diseases (NIAID). 24 January 2019. Retrieved 12 August 2019.
  7. Public Domain This article incorporates text from this source, which is in the public domain: "FDA Approves First Treatment for Ebola Virus". U.S. Food and Drug Administration (FDA) (Press release). 14 October 2020. Retrieved 14 October 2020.
  8. "Guidelines for Evaluation of US Patients Suspected of Having Ebola Virus Disease". Centers for Disease Control and Prevention (CDC). 1 August 2014. Archived from the original on 8 August 2014. Retrieved 5 August 2014.
  9. Roberts D. "Ebola CDC director warns Ebola like 'forest fire' as Congress readies for hearing - Ebola crisis live updates". The Guardian. Retrieved 1 October 2014.
  10. "Three leading Ebola experts call for release of experimental drug". Los Angeles Times. 6 August 2014.
  11. "In Ebola Outbreak, Who Should Get Experimental Drug?". The New York Times. 8 August 2014.
  12. "Ethical considerations for use of unregistered interventions for Ebola viral disease (EVD)". World Health Organization (WHO). 12 August 2014. Archived from the original on 12 August 2014.
  13. Briggs H (7 August 2014). "Ebola: Experimental drugs and vaccines". BBC News Online. Retrieved 1 August 2014.
  14. Park A (19 December 2014). "How Your Tablet Can Help Find an Ebola Cure". Retrieved 19 December 2014.
  15. "Ebola 2.0 – Lessons Learned in 2014 May Not Suffice". Africa Times. 22 May 2017. Archived from the original on 23 May 2017. Retrieved 25 May 2017.
  16. Seppa N (29 August 2014). "ZMapp drug fully protects monkeys against Ebola virus". Science News. Society for Science & the Public. Retrieved 1 October 2014.
  17. Tosh PK, Sampathkumar P (December 2014). "What clinicians should know about the 2014 Ebola outbreak". Mayo Clinic Proceedings. 89 (12): 1710–7. doi:10.1016/j.mayocp.2014.10.010. PMID 25467644.
  18. Kroll D (26 August 2014). "How will we know if the Ebola drugs worked?". Forbes. Retrieved 1 October 2014.
  19. "Liberia-U.S. clinical research partnership opens trial to test Ebola treatments" (Press release). National Institutes of Health (NIH). Retrieved 27 February 2015.
  20. "Press release: Study Finds Ebola Treatment ZMapp Holds Promise, Although Results Not Definitive". National Institute of Allergy and Infectious Diseases (NIAID). 12 October 2016.
  21. Bixler SL, Duplantier AJ, Bavari S (2017). "Discovering Drugs for the Treatment of Ebola Virus". Current Treatment Options in Infectious Diseases. 9 (3): 299–317. doi:10.1007/s40506-017-0130-z. PMC 5570806. PMID 28890666.
  22. Dhama K, Karthik K, Khandia R, Chakraborty S, Munjal A, Latheef SK, et al. (2018). "Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus". Frontiers in Immunology. 9: 1803. doi:10.3389/fimmu.2018.01803. PMC 6095993. PMID 30147687.
  23. "Two new Ebola drugs dramatically boost survival in a clinical trial". www.pbs.org. 12 August 2019. Retrieved 27 October 2019.
  24. Moekotte AL, Huson MA, van der Ende AJ, Agnandji ST, Huizenga E, Goorhuis A, et al. (November 2016). "Monoclonal antibodies for the treatment of Ebola virus disease". Expert Opinion on Investigational Drugs. 25 (11): 1325–1335. doi:10.1080/13543784.2016.1240785. PMID 27676206. open access
  25. Hayden EC (25 February 2016). "Ebola survivor's blood holds promise of new treatment". Nature. doi:10.1038/nature.2016.19440. S2CID 211835755.
  26. Corti D, Misasi J, Mulangu S, Stanley DA, Kanekiyo M, Wollen S, et al. (March 2016). "Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody". Science. 351 (6279): 1339–42. Bibcode:2016Sci...351.1339C. doi:10.1126/science.aad5224. PMID 26917593.
  27. Clinical trial number NCT03478891 for "Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults" at ClinicalTrials.gov
  28. Gatherer D (August 2014). "The 2014 Ebola virus disease outbreak in West Africa". The Journal of General Virology. 95 (Pt 8): 1619–24. doi:10.1099/vir.0.067199-0. PMID 24795448.
  29. Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S (May 2014). "Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model". Antiviral Research. 105: 17–21. doi:10.1016/j.antiviral.2014.02.014. PMID 24583123.
  30. "Guinea: Clinical Trial for Potential Ebola Treatment Started in MSF Clinic in Guinea". AllAfrica – All the Time. Retrieved 28 December 2014.
  31. Clinical trial number NCT02329054 for "Efficacy of Favipiravir Against Ebola (JIKI)" at ClinicalTrials.gov
  32. "Fujifilm's Toyama unit set to publish promising early clinical results in treating Ebola". Retrieved 7 February 2015.
  33. Kroll D (29 August 2014). "BioCryst to Launch NHP Ebola Drug Safety, Efficacy Studies 'Within Weeks'". Forbes. Retrieved 5 October 2014.
  34. "DURHAM: BioCryst receives additional funding for Ebola drug". WNCN. 18 September 2014. Archived from the original on 6 October 2014. Retrieved 5 October 2014.
  35. Clinical trial number NCT02319772 for "A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430" at ClinicalTrials.gov
  36. "BioCryst's Ebola drug shows promise in animal study". Reuters. 23 December 2014. Retrieved 27 December 2014.
  37. Staff (3 September 2014). "Chimerix experimental drug shows promise in fighting Ebola virus". WNCN. Archived from the original on 18 February 2015. Retrieved 7 October 2014.
  38. "Trials of untested Ebola drugs begin in West Africa". Reuters. Retrieved 6 January 2015.
  39. "Chimerix's Brincidofovir Selected for Use in Ebola Clinical Trial in West Africa by International Consortium". Chimerix, Inc. Archived from the original on 11 July 2015. Retrieved 1 August 2015.
  40. "Chimerix Ends Brincidofovir Ebola Trials To Focus On Adenovirus And CMV". Forbes. Retrieved 31 January 2015.
  41. Kupferschmidt K (11 March 2015). "New Ebola drug trial starts in Sierra Leone". Science Magazine. doi:10.1126/science.aab0304.
  42. Vogel G, Kupferschmidt K (19 June 2015). "In setback for potential Ebola drug, company halts trial". Science Magazine. doi:10.1126/science.aac6876.
  43. Blum K. "Drug Targeting Ebola Virus Protein VP24 Shows Promise in Monkeys". mBiosphere. American Society for Microbiology. Retrieved 1 August 2015.
  44. "AVI 6002 (AVI-7537) Drug Therapy (Sarepta Therapeutics) for Treating Ebola Virus Disease". ECRI Institute. Retrieved 1 August 2015.
  45. Heald AE, Iversen PL, Saoud JB, Sazani P, Charleston JS, Axtelle T, et al. (November 2014). "Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against Ebola virus and Marburg virus: results of two single-ascending-dose studies". Antimicrobial Agents and Chemotherapy. 58 (11): 6639–47. doi:10.1128/AAC.03442-14. PMC 4249403. PMID 25155593.
  46. Clinical trial number NCT01353027 for "Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus" at ClinicalTrials.gov
  47. Clinical trial number NCT01593072 for "A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers" at ClinicalTrials.gov
  48. "China approves Ebola drug for emergency use. Kristine Yang, Bioworld.com". BioWorld.
  49. "China sends Ebola drug to Africa, eyes clinical trials". Reuters. 16 October 2014. Retrieved 31 October 2014.
  50. "Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease Empirical treatment during outbreaks". World Health Organization (WHO). Retrieved 4 October 2014.
  51. Maxmen A (16 February 2015). "Blood transfusions show early promise as possible Ebola cure". Al Jazeera America. Retrieved 1 August 2015.
  52. Butler D (15 December 2014). "First trials of blood-based Ebola therapy kick off". Nature. doi:10.1038/nature.2014.16564. S2CID 76411229.
  53. Mupapa K, Massamba M, Kibadi K, Kuvula K, Bwaka A, Kipasa M, et al. (February 1999). "Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee". The Journal of Infectious Diseases. 179 Suppl 1 (s1): S18–23. doi:10.1086/514298. PMID 9988160.
  54. Goeijenbier M, van Kampen JJ, Reusken CB, Koopmans MP, van Gorp EC (November 2014). "Ebola virus disease: a review on epidemiology, symptoms, treatment and pathogenesis". The Netherlands Journal of Medicine. 72 (9): 442–8. PMID 25387613.
  55. Chippaux JP (October 2014). "Outbreaks of Ebola virus disease in Africa: the beginnings of a tragic saga". The Journal of Venomous Animals and Toxins Including Tropical Diseases. 20 (1): 44. doi:10.1186/1678-9199-20-44. PMC 4197285. PMID 25320574.
  56. Butler, Declan (1 December 2014). "Ebola experts seek to expand testing". Nature. 516 (7530): 154–155. Bibcode:2014Natur.516..154B. doi:10.1038/516154a. ISSN 1476-4687. PMID 25503213. S2CID 4409762.
  57. Paddock C (9 January 2015). "'Lab in a suitcase' set to improve Ebola virus control". Medical News Today. Retrieved 11 April 2015.
  58. Falconi M (29 December 2014). "Roche Secures Emergency Approval by U.S. Regulators for Ebola Test". The Wall Street Journal. Retrieved 29 December 2014.
  59. "MIT designs 10-minute ebola test". gizmag.com. 25 February 2015. Retrieved 26 February 2015.
  60. "FDA approves Corgenix's Ebola test for emergency use". Reuters. 26 February 2015. Retrieved 27 February 2015.
  61. O'Carroll L (29 March 2015). "Ebola rapid diagnostic kit developed by UK scientists in Sierra Leone". The Guardian. Retrieved 10 April 2015.
  62. "Cialis Generic 20mg India - CommentAboutDrugs". drugscomment.com. Retrieved 26 May 2020.
  63. "New Ebola Treatment Filters Virus Out of the Blood". Time. Retrieved 3 January 2015.
  64. "FDA allows testing of Aethlon device in Ebola patients". Reuters. 2 January 2015. Retrieved 2 January 2015.

Further reading
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.